Tortugas Neuroscience Raises $106M to Advance Clinical-Stage Neurology Drugs for Schizophrenia, Epilepsy, and Tinnitus

Biotech doesn’t usually make a grand entrance with receipts in hand, but Tortugas Neuroscience skipped the small talk and walked in mid-conversation. Straight out of Framingham with $106M across Seed and Series A, the company arrives carrying 4 clinical-stage programs like it’s been building in the shadows while everyone else was still sketching on whiteboards. No theatrics, just assets, timing, and a very clear sense of where the puck is going in CNS.

Jeff Jonas, M.D. and Al Robichaud, Ph.D. didn’t stumble into this. They’ve been through the CNS gauntlet at Sage Therapeutics, where you learn quickly that the brain doesn’t negotiate and the market doesn’t wait. Now they’re running a tighter operation, built on derisked mechanisms and assets already sitting in Phase 2, licensed from Eisai and Jiangsu Hansoh Pharmaceutical Group. Translation for the casual observer: less guesswork, more execution. TRTL-107 targeting schizophrenia, a GABA modulator for tinnitus, a GAT-1 inhibitor for focal epilepsy, and a PDE9 inhibitor aimed at reversible encephalopathies. It’s a lineup that reads like a neurology syllabus with teeth.

Cure Ventures didn’t just write a check, they lit the fuse early as founding investor and came back to co-lead the Series A alongside The Column Group and AN Venture Partners. That kind of repeat conviction usually means the story made sense before the press release ever hit the wire. When you see capital stack like that, it’s less about hype and more about pattern recognition. Back teams who know the terrain, back assets that already cleared the first set of scientific hurdles, and back indications where regulators and markets actually know how to respond.

What’s interesting here isn’t just the size of the round, it’s the posture. Tortugas isn’t chasing novelty for novelty’s sake. They’re leaning into known biology, large patient populations, and regulatory paths that don’t require a Ouija board to navigate. In a space where timelines stretch and certainty shrinks, that kind of discipline feels almost rebellious.

And if you’re building in biotech, there’s a lesson tucked in plain sight. You don’t always need to invent from zero. Sometimes the smarter play is knowing where the signal already exists, having the credibility to access it, and the discipline to move it forward without getting distracted by shiny science that never leaves the lab. Tortugas didn’t just raise capital. They bought themselves time, focus, and a real shot at outcomes that matter.